Kiniksa Pharmaceuticals International, PLC
kiniksa.comWhat Do They Do?
Sells ARCALYST, a treatment for recurrent pericarditis and other inflammatory conditions, and develops antibody therapies for cardiovascular and autoimmune diseases.
10-K for FY2025, filed Feb 24, 2026We are a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on…View ↗
We received FDA approval of ARCALYST for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children…View ↗
KPL-387 is an investigational, fully human immunoglobulin G2 monoclonal antibody that binds human interleukin-1 receptor 1 (“IL-1R1”)…View ↗
Abiprubart is an investigational monoclonal antibody inhibitor of CD40-CD154 costimulatory interaction, which we believe to be an…View ↗
How Do They Make Money?
Sells ARCALYST to specialty pharmacies and distributors, typically getting paid when the medicine ships; it also receives license and collaboration payments, royalties and milestone payments from partners.
10-K for FY2025, filed Feb 24, 2026We have been generating product revenue from sales of ARCALYST since April 2021. ARCALYST is sold through a third party logistics provider…View ↗
Net revenue from product sales is recognized at the transaction price when the customer obtains control of our product, which occurs at a…View ↗
License and collaboration revenue includes amounts recognized related to upfront payments, royalty revenue, milestone payments and products…View ↗
Under the Huadong Collaboration Agreements, we received a total upfront cash payment of $22.0 million, which includes $12.0 million for the…View ↗
Following the FDA approval of ARCALYST in March 2021, the Company began generating product revenue from sales of ARCALYST. ARCALYST is sold…View ↗
Net revenue from product sales is recognized at the transaction price when the specialty pharmacy or specialty distributors obtains control…View ↗
$677.6M
-
10-K for FY2025, filed Feb 24, 2026
$677.6M ↗
Who Are Their Customers?
Specialty pharmacies and specialty distributors buy ARCALYST through a third-party logistics provider and deliver it to patients by mail. Huadong holds exclusive development and commercialization rights for ARCALYST in its territory.
10-K for FY2025, filed Feb 24, 2026We have been generating product revenue from sales of ARCALYST since April 2021. ARCALYST is sold through a third party logistics provider…View ↗
In February 2022, we entered into the Huadong Collaboration Agreements with Huadong, pursuant to which we granted Huadong exclusive rights…View ↗
Under the Huadong Collaboration Agreements, we received a total upfront cash payment of $22.0 million, which includes $12.0 million for the…View ↗
Following the FDA approval of ARCALYST in March 2021, the Company began generating product revenue from sales of ARCALYST. ARCALYST is sold…View ↗
Do Revenues Turn Into Profits?
Yes. It kept 9 cents of every revenue dollar as net income in FY2025 and turned 20 cents into free cash flow.
10-K for FY2025, filed Feb 24, 2026
$77.2MView ↗
10-K for FY2025, filed Feb 24, 2026
$59MView ↗
10-K for FY2025, filed Feb 24, 2026
$136.4MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Jul 28, 2026
$25.4MView ↗
- ▲ +43%
- vs $17.8M in Q2 FY2025
-
Jul 28, 2026
Raised 2026 ARCALYST revenue guidance
The expected range increased to $980 million to $995 million from $930 million to $945 million.
Sources
8-K, filed Jul 28, 2026
Kiniksa expects 2026 ARCALYST net product revenue of between $980 million and $995 million, compared to prior guidance of between $930…View ↗
Growing. Revenue grew 17.6x in 4 years, from $38.5M in FY2021 to $677.6M in FY2025, about 105% a year.
A narrower pipeline focus
The older report described cardiovascular and autoimmune assets, including candidates for autoimmune diseases. The latest report focuses on cardiovascular diseases, discusses antibody candidates for pericarditis, and says development of an autoimmune candidate for Sjögren’s Disease was discontinued.
10-K for FY2022, filed Mar 2, 2023 10-K for FY2025, filed Feb 24, 2026We are a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on…View ↗
KPL-387 is an investigational, fully human immunoglobulin G2 monoclonal antibody that binds human interleukin-1 receptor 1 (“IL-1R1”)…View ↗
We previously announced a Phase 2b clinical trial of abiprubart in Sjögren’s Disease. In February 2025, we announced our plans to…View ↗
Who Do They Compete With?
Competes with Cardiol Therapeutics, R-Pharm International, Ventyx Biosciences, Monte Rosa Therapeutics, Swedish Orphan Biovitrum AB, Abbvie, Novartis Pharmaceuticals, Zydus Lifesciences, Halia, Olatec Therapeutics, NodThera, Roche, Sunshine Guojian Pharmaceuticals, XBIOTECH, Avalo Therapeutics, Cantargia, Pacira Biosciences, Sanofi, Almirall, and Ventus Therapeutics
10-K for FY2025, filed Feb 24, 2026Recurrent Pericarditis: We are not aware of any other FDA-approved therapies for recurrent pericarditis, but we are aware of several…View ↗
Loading...
